Skip to Main Content

The FDA’s decision on Friday to approve a new blood thinner from Portola Pharmaceuticals has biotech investors optimistic that the agency, now under new management, will be easier to get along with than administrations past.

Portola’s drug, called Bevyxxa, overcame what could have been a damning clinical result — it failed to show statistically significant benefits over an old generic. It’s now approved to prevent blood clots in patients who’ve been hospitalized for medical illness but didn’t require surgery.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.